Insulet Corporation (NASDAQ:PODD) reported strong Q1 results with $761.7M revenue and EPS above estimates driven by Omnipod sales, but a Class I FDA recall of Omnipod Pods over serious-injury risk has reduced device availability and sent the stock down about 5.5%.

Previous Week Recap

  • Omnipod Pods Recall Class I: FDA classed Insulet’s Omnipod Pods recall as Class I, citing risk of serious injury; recall covers affected product line and status, impacting PODD’s device availability and risk profile
  • Insulet Q1 Revenue Jump: Insulet (PODD) Q1 revenue $761.7M, +33.9% YoY; EPS beat estimates. Strong Omnipod sales noted. Stock dropped ~5.5%, trading near $158.37.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.